Dr. NP should step aside and assist the BOD in a search for a seasoned BioTech CEO. As a significant investor since 2015, I have been a supporter of Dr. NP and appreciate his getting the company to this point. That said, he simply does not have the knowledge, experience, skills, nor the temperament to lead Cytodyn to its deserving place as a biomedical contributor which fulfills the potential of Leronlimab. Too many missteps and poor understanding of the regulatory landscape has cost the company dearly.
Again, what is required of a CEO now and in the future is an array of personal, business, and industry skills which Dr. NP simply does not possess. In a perfect world Dr NP would contribute in the future in a role commensurate with and supportive of his successor.